Chapter 68: Other Gastrointestinal Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine you eat, like, a piece of really questionable seafood.

Oh yeah, we've all been there.

Right.

And within a few hours, your body initiates this violent, highly coordinated, and honestly incredibly efficient evacuation protocol.

It is brutal, but very effective.

Exactly.

And, you know, we tend to think of the gastrointestinal tract as just simple plumbing.

Food goes in, it gets processed, waste comes out.

It's a series of pipes.

Yeah.

But if the gut were just mechanical pipes, treating a stomach issue would be as simple as clearing a clog.

Which it definitely isn't.

Right.

Instead, I mean, treating a pregnant patient's morning sickness requires an entirely different chemical strategy than treating, say, a sailor's sea sickness.

Because the gut is actually this highly sensitive, intensely wired surveillance network.

I mean, it has its own nervous system, and it's constantly communicating with your brain, your immune system.

Your circulatory system.

Exactly.

So when we introduce a drug into that environment, we aren't just adjusting a pipe, we're manipulating a really complex neurological and chemical conversation.

Well, welcome to this deep dive.

Think of today as a personalized one -on -one tutoring session with the Last Minute Lecture Team.

Glad to be here.

Our mission today is to help you logically master the pharmacology of the gut.

And we're pulling this directly from Chapter 68 of Lynn's Pharmacotherapeutics.

But we're definitely throwing out rote memorization.

Yes, please.

Flashcards won't help you when you're an advanced practice nurse or a PA staring down a complex patient chart.

Right.

We're going to build a clinical framework where the underlying pathophysiology actually dictates your therapeutic goals, your drug selection, and most importantly, your safety monitoring.

Okay, let's unpack this.

Let's start with that evacuation protocol you mentioned earlier, the emetic response.

Vomiting.

Yeah, to stop it, we really have to know where the signal originates.

Right.

So where's the command center?

It's a cluster of neurons in the medulla oblongata called the vomiting center.

In the brainstem?

Exactly.

And it receives distress signals through two main avenues.

So the direct route is pretty straightforward.

Like what?

Signals from the cerebral cortex triggered by overwhelming fear or signals from the vestibular apparatus in your inner ear when you spin around too fast.

Okay, so that's the direct route.

Right.

But a lot of severe nausea doesn't start in the brain or the ear.

Right.

Like, if a patient is receiving intravenous chemotherapy,

those toxins are circulating in the blood.

How does the brain even know they're there to trigger the vomiting center?

That happens through the indirect route, which relies on this fascinating structure called the chemoreceptor trigger zone, the CTZ.

The CTZ, okay.

Yeah, and the CTZ sits just outside the blood -brain barrier.

It's constantly sampling the blood and the cerebrospinal fluid for toxic compounds.

Like a chemical smoke detector.

Exactly.

When it detects blood -borne emetics like chemo or opioids or when it gets distress signals traveling up the vagal nerves from an irritated stomach, the CTZ fires an alarm to the vomiting center.

Right.

Which then executes the actual physical vomiting reflex.

So if the CTZ is the alarm bell, that perfectly explains the mechanism of our most effective class of antimedics.

The serotonin receptor antagonist.

Yeah.

And the famous prototype here is Ondansetron or Zofran.

A classic.

Right.

It selectively blocks type 3 serotonin receptors, the 5 -HT3 receptors that are located directly in the CTZ and on those vagal nerves in the stomach.

Right.

So it's essentially...

Is it like putting noise -canceling headphones on the CTZ?

Yes.

That is a great analogy.

The chemotherapy is screaming, you know, poison in the blood, but the CTZ literally cannot hear the signal.

So it never tells the brain to vomit.

Exactly.

And what's fascinating here is that precise targeting makes it highly effective for chemotherapy -induced nausea and vomiting CIMV without causing those involuntary muscle spasms.

The extra -pure middle effects.

Right.

Which really plague the older nausea medications.

But you know, pharmacology always demands a trade -off.

It always does.

By blocking serotonin receptors so heavily, Ondansetron introduces a severe cardiac risk.

It can prolong the QT interval on an electrocardiogram.

I want to pause on that because we hear prolonged QT a lot in pharmacology.

But let's visualize what that actually means for a beating heart.

Okay.

So think of the heartbeat as an electrical spark followed by a mandatory reset period.

Okay.

The QT interval represents that reset time.

Ondansetron can stretch that reset window out.

And if it takes too long?

If the heart takes too long to reset and the next electrical spark hits early, the heart's rhythm degrades into this chaotic, twisting electrical storm.

Sores de pointe.

The heart stops pumping blood and just quivers.

Which can be fatal.

Absolutely fatal.

Which grounds the clinical monitoring rule in pure logic.

You can't just hand out Ondansetron to everyone.

No you can't.

The safety priority mandates a baseline ECG and an electrolyte panel.

You have to use extreme caution in patients with heart failure, bradycardia, or low potassium and magnesium.

Wow.

Okay, let's build on that because for highly immunogenic chemotherapy, Ondansetron alone just isn't enough.

Right.

CINV has an acute phase and a deline phase.

To handle the full spectrum, clinical guidelines actually recommend polypharmacy.

Combining drugs.

Combining Ondansetron, a glucocorticoid like dexamethasone, and a drug called a prepotent.

Now I've got a bone to pick with a prepotent.

Oh really?

Yeah, the text explicitly calls it only moderately effective on its own.

So why are we throwing a mediocre drug into a heavy -hitting chemotherapy regimen?

It's all about synergistic blockade.

A prepotent targets a completely different alarm system.

It blocks substance P or neurokinin -1 receptors in the CTZ and it has a remarkably long duration of action.

So while Ondansetron knocks out the acute serotonin signals, a prepotent acts as this long -acting shield against the delayed pathways.

So you're essentially locking both the front and the back doors to the vomiting center.

Exactly.

But bringing a prepotent into the mix introduces a massive pharmacokinetic headache for the clinician, right?

Yeah.

I mean, the drug profile is incredibly messy when it comes to the liver.

Oh, it's a nightmare.

So the liver is the body's chemical processing factory and the CYP3A4 enzyme is its busiest assembly line.

Okay.

A prepotent acts like a highly disruptive floor manager.

First, it hogs the CYP3A3 assembly line and actively inhibits it.

Which causes a massive traffic jam for any other drugs trying to use that line.

Right.

And dexamethasone, the steroid we just mentioned using in this combo, relies on CYP3A4.

So if a prepotent stops the assembly line, the dexamethasone backs up in the bloodstream.

Which leads to steroid toxicity.

So the clinician actually has to proactively lower the steroid dose.

But a prepotent's disruption doesn't stop there.

While it shuts down CYP3A4, it walks over to a completely different assembly line, CYP2D6.

Oh no.

Yeah.

And it aggressively speeds it up.

It induces the enzyme.

So this hyperactive assembly line starts breaking down drugs much faster than normal.

Exactly.

Meaning they clear the body before they can even work.

Warfarin and ethanol estradil are processed here.

Okay.

That is a massive patient education moment.

Huge.

If you speed up the breakdown of warfarin, the patient's blood could clot.

You have to monitor coagulation tightly.

Right.

And if you speed up the breakdown of oral contraceptives, ethanol estradil,

the birth control fails.

You have to counsel that patient to use non -hormonal backups.

Precisely.

Now, older classes of antimedics carry their own strict warnings, too, specifically the dopamine antagonists.

Like the phenothiazines, promethazine.

Yep.

And butyrophenones, like dropertol, they work by blocking dopamine 2 receptors in the CTZ.

But the FDA has slapped severe black box warnings on these.

Very severe.

Dictating non -negotiable clinical boundaries?

Let's look at promethazine.

Which people think of as a pretty common drug for sick kids, right?

They do, but the black box warning makes it absolutely contraindicated in children under two years old.

Because it causes sudden severe respiratory depression.

Yes.

Deaths have occurred.

It's incredibly dangerous.

Wow.

And the second warning for promethazine is just as severe, and it involves the route of administration.

The IV route.

Right.

If you give it intravenously and the IV line slips, allowing the drug to leak into the surrounding tissue, a process called extravasation, the chemical nature of promethazine will literally destroy the tissue cell by cell.

Oh, that's terrifying.

It causes severe necrosis and gangrene that can literally require amputation.

So intramuscular injection is the preferred route to avoid that catastrophic risk.

Makes sense.

And its cousin, dropertol, carries a black box warning for the exact same fatal dysrhythmia we saw with Ondansetron.

Profound QT prolongation.

You just cannot give dropertol without a 12 -lead ECG first.

Period.

Okay, so we've covered the heavy chemical cheddars in the blood.

Yeah.

But what about a pregnant patient dealing with severe morning sickness?

Right.

Here's where it gets really interesting, because you certainly aren't going to start them on a harsh dopamine blocker.

No, absolutely not.

The clinical guideline for nausea and vomiting of pregnancy or NVP requires a much gentler touch.

And the first -line therapy is surprisingly simple, right?

It is.

Backed by rigorous trials, it's a fixed -dose combination of an antihistamine called doxylamine and vitamin B6, which is pyridoxin.

The trade name is texlegis.

Right.

And it drops NVP symptoms by about 70 % without posing any risk to fetal development.

What if that fails?

Clinicians might carefully step up to procorperazine or metoclopramide, but the text draws a really hard line on glucocorticoids.

Like methylprednisolone.

Exactly.

It is a last resort, and it is strictly forbidden before 10 weeks of gestation.

Because using it during that critical early developmental window drastically increases the risk of the fetus developing a cleft lip.

Right.

It's a major safety priority.

Let's contrast pregnancy nausea with motion sickness.

Okay.

If you're on a boat in Rye Seas, your CTZ isn't detecting poisons in your blood.

The distress signal is coming from the vestibular apparatus in your inner ear.

Right.

The pathways connecting your ear to the vomiting center don't use serotonin or dopamine.

They communicate using acetylcholine and histamine.

Which means giving Zofran to a C6 sailor is largely useless.

Completely useless.

You have to match the drug to the pathway.

The absolute gold standard here is scopolamine.

Which is a muscarinic antagonist.

It blocks those acetylcholine signals.

Exactly.

And the brilliance of scopolamine is the transdermal patch delivery system that you put behind the ear.

Because if you took it as an oral pill, you'd be hit with a massive systemic dose of an anti -cholinergic.

You'd have severe cotton mouth, blurred vision, urinary retention.

But the patch slowly drips the drug directly into the local tissue.

Right.

Giving you a steady blockade with just a fraction of the side effects.

Nice.

Do people still use antihistamines for motion sickness?

They do, yeah.

Drugs like diamond hydronate dryamamine.

They block both histamine and muscarinic receptors, but they cross into the brain and cause heavy sedation.

And this brings up a vital geriatric safety alert.

Older adults are incredibly sensitive to anti -cholinergic medications.

So in the elderly, drugs like diamond hydronate can precipitate sudden, severe confusion and acute delirium.

They should generally just be avoided in that population.

Wow.

Okay, so we spent the first half of this deep dive exploring how the body violently expels threats upward.

Yes, we have.

Let's shift our focus downward.

What happens when the gut tries to aggressively flush things out the other end?

Diarrhea.

Let's talk about diarrhea.

So diarrhea is an excessive volume and fluidity of stool, usually driven by hyperactive intestinal motility.

The transit time is so fast, the bowel literally doesn't have time to reabsorb water.

And the most effective pharmacological brakes we have for this are actually opioids.

They are.

Wait, I always find that wild.

We are in the middle of an opioid epidemic, and the text says we use opioids for a stomach bug.

That sounds like a massive public health risk.

I mean, it would be, if it weren't for brilliant pharmaceutical engineering.

Opioids activate most receptors in the gut, which paralyzes intestinal motility, dramatically slows transit, and allows water to be reabsorbed.

Okay, but how do we get that benefit without the addiction risk?

Manufacturers created diphenoxylate, trade name Lomotil.

It's an opioid formulated exclusively for diarrhea, but, and here's the genius part, they booby -trapped the pill.

Booby -trapped it.

Yeah.

They mixed the opioid with a subtherapeutic dose of atropine, which is a harsh anticholinergic.

Oh, I see.

So if a patient takes the prescribed dose to stop their diarrhea, the atropine level is too low to notice.

Exactly.

No problem at all.

But if someone tries to abuse it by swallowing a handful of pills to chase a high, they trigger the chemical trap.

Yes.

They ingest a massive toxic dose of atropine, which induces a miserable nightmare of extreme dry mouth, racing heart, and urinary retention.

So the formulation physically punishes abuse.

A perfect example of leveraging side effects for safety.

But this raises an important question when dealing with infectious diarrhea.

Like traveler's diarrhea caused by E.

coli.

Right.

Should we always stop the bowel?

Diarrhea is essentially a defense mechanism clearing a pathogen.

Right.

It's trying to get the bug out.

So if a patient has a mild case of E.

coli and you give them an opioid like loperamide to paralyze the gut.

You are trapping the multiplying bacteria inside the intestine.

Exactly.

Prolonging the infection and the tissue damage.

You're treating the symptom but turbocharging the disease.

Yes.

So if the infection is severe with fever and bloody stools, the tech says to leave the motility alone and target the actual invader with a short course of antibiotics.

Like isithromycin or rifaximin.

Exactly.

Okay.

Let's transition to a condition where there is no infectious invader and no visible structural damage.

Irritable bowel syndrome or IBS.

Right.

So in IBS, the bowel appears completely normal on a scan.

But the nervous system wiring is hyper responsive and hypersensitive.

Normal striking from a meal triggers an exaggerated agonizing pain response and erratic motility.

And because it's a functional disorder of the nervous system, over -the -counter antidiarrheals usually fail.

So what do we use?

To calm that hyperactive pain network, clinicians often use tricyclic antidepressants or TCA's.

Wait, really?

Antidepressants for stomach pain?

Yes.

But to be clear, the dose used here is much lower than what's used for depression.

It's not treating a mood disorder.

Oh.

It's chemically dampening the visceral pain signals traveling from the gut to the brain.

Makes sense.

But when those nonspecific treatments fail, we move to specialized drugs, like Allostron.

Trade name?

Lotronex.

Right.

And it's approved strictly for women with severe chronic diarrhea predominant IBS.

Yes.

IBSD.

And Allostron selectively blocks those same 5 -HT3 serotonin receptors we discussed with Emesis, but down in the bowel, right?

Exactly.

And blocking serotonin down there significantly slows colonic transit time and firms up the stool.

But slowing the bell down carries a terrifying black box warning.

It does.

Allostron can work too well.

If the transit stops entirely, it can cause severe,

fatal constipation, resulting in bowel perforation.

Or it can cause ischemic colitis, where the sluggish bowel literally cuts off its own blood supply, leading to tissue death.

So the clinician's reasoning framework here has to be uncompromising.

Absolutely.

Allostron is strictly contraindicated in anyone with a history of chronic constipation, obstruction, ischemic colitis, or diverticulitis.

Because the risk of death is real.

It is real.

The FDA actually requires both the prescriber and the patient to enroll in a highly controlled risk management program.

Wow.

And at the very first sign of constipation or rectal bleeding, the drug must be stopped immediately.

Now, the strict rules for IBS contrast pretty heavily with inflammatory bowel disease or IBD.

Right.

While IBS has no visible damage, IBD, which includes Crohn's disease and ulcerative colitis, is a structural disease.

The immune system launches a massive destructive inflammatory attack against the normal bacteria living in the bowel.

Tearing up the intestinal lining.

So our therapeutic goal completely shifts.

We aren't trying to slow motility anymore.

We must suppress the immune system's friendly fire.

And the text outlines a stepwise approach for this.

Yes.

Starting with five amino salicylates.

Like sulfasalazine.

Exactly.

Now, the pharmacokinetics of sulfasalazine are basically a Trojan horse delivery system relying on the patient's own gut bacteria.

I love this mechanism.

Right.

You swallow the pill and it does absolutely nothing until it reaches the intestine.

Yep.

There, the local bacteria break it apart into two molecules,

5 -ASA and sulfapyridine.

Right.

And the 5 -ASA is the hero.

It coats the intestinal wall, putting out the inflammatory fire locally.

But the other half, the sulfapyridine, is the villain.

Very much so.

It gets absorbed into the patient's bloodstream and causes systemic adverse effects.

Like what?

It can suppress the bone marrow, leading to agranulocytosis and hemolytic anemia.

So the clinician has to continuously monitor the patient's complete blood count.

Exactly.

CBC monitoring is non -negotiable.

Okay.

So when 5 -AMC salicylates aren't strong enough, we step up to glucocorticoids.

Yes.

And the standout here is oral butynide, trade name Entocort EC.

Is this like a delayed release smart bomb?

That is exactly what it is.

We know systemic steroids cause terrible long -term damage, right?

Brittle bones, adrenal suppression.

Yeah.

Nobody wants systemic steroids long -term.

But butynide capsules are engineered to survive the stomach acid and only dissolve when they reach the specific pH of the inflamed ullium and ascending colon.

They detonate right on the target tissue.

Right.

And any butynide that does leak into the bloodstream is immediately swept to the liver, where it undergoes massive first -pass metabolism.

So the liver basically destroys it before it can circulate, protecting the rest of the body from systemic steroid toxicity.

Brilliant design.

Very cool.

But for severe refractory IBD, when the inflammation simply won't yield, we have to bring in the heavy artillery.

Immunosuppressants and immunomodulators.

Let's talk about those.

Theoprenes like azathioprine are potent immunosuppressants.

But the crucial clinical pearl you have to remember is their delayed onset.

How delayed.

Azathioprine can take up to six months to reach therapeutic levels.

Wait, six months?

So you would never use it to stop an acute flare -up?

Never.

It is strictly for maintaining long -term remission.

And because you are suppressing the bone marrow, you risk neutropenia and pancreatitis.

So for faster, aggressive intervention, clinicians use immunomodulators like infliximab, trade name Remicade.

Right.

It's an IV infusion of monoclonal antibodies.

They act like heat -seeking missiles.

Hunting down and neutralizing TNF -alpha, which is a primary trigger for inflammation.

And it works beautifully.

It induces remission in a third of severe Crohn's patients.

But… Always.

Always.

If you neutralize a key pillar of the immune system, you leave the gates wide open.

Clinicians must vigilantly monitor for opportunistic infections.

Right.

Patients on infliximab are at high risk for developing tuberculosis, severe fungal infections, and even lymphoma.

Wow.

Okay, so we've talked about spelling, slowing down, and suppressing the gut.

To wrap up, what if the clinical goal is to speed the gut up?

Enter the prokinetics, like metoclopramide or reglin.

So what does this all mean for motility?

It increases upper GI motility by enhancing the action of acetylcholine, forcing the stomach to empty faster.

Okay, so it's used for conditions like diabetic gastroparesis, where the stomach is functionally paralyzed?

Exactly.

But pushing motility carries immense risk.

Think about it.

If a patient has a mechanical bowel obstruction, a perforation, or a GI hemorrhage… Oh!

Aggressively stimulating the stomach to pump food forward against a closed or bleeding pipe.

It will cause a catastrophic rupture.

It is strictly contraindicated in those scenarios.

In the most total sense.

Furthermore, long -term or high -dose use of metoclopramide can cause irreversible tardive dyskinesia.

Those are the repetitive, involuntary movements of the face and limbs.

Right.

Treatment must be brief and at the lowest possible dose, especially in older adults.

Okay.

The text finishes with a few localized treatments.

For patients with cystic fibrosis or pancreatitis who can't secrete digestive enzymes, we use pancreolipase.

Right.

Simple replacement capsules containing lipases, amylases, and proteases derive from hog pancreas to digest fats and proteins.

And finally, there's a fascinating dual -use drug for anorectal conditions.

Nitroglycerin.

Yeah.

Most clinicians know a 4 .4 % nitroglycerin ointment as a treatment for chest pain.

Right.

It relaxes the blood vessels around the heart.

But when applied topically to a chronic anal fissure, the exact same mechanism provides incredible relief.

Nitroglycerin is a pertinent, smooth muscle relaxant.

So it relaxes the internal anal sphincter, breaking the cycle of debilitating spasms and increasing blood flow to heal the tear.

Exactly.

A perfect demonstration of how a single chemical mechanism can solve vastly different clinical problems based purely on where it's deployed.

That's amazing.

Let's synthesize everything we've unpacked today.

We didn't just memorize a list of gastrointestinal drugs.

We analyzed the body's internal logic.

Is the gut violently expelling a toxin?

We block the CTZ receptors.

Is it dumping fluid too quickly?

We use targeted opioids to hit the brakes.

Is the immune system tearing the bowel apart?

We deploy stepwise anti -inflammatories.

And at every single decision point, we weighed the black box warnings from respiratory depression and tissue necrosis to fatal dysrhythmias and ischemic colitis.

All to ensure the safety of your future patients.

Exactly.

You know, as you integrate this into your clinical practice, I want to leave you with one final observation from the text.

Let's hear it.

Notice how the primary medications we use to control the gut 5 -HT3 antagonists for vomiting, dopamine blockers for motility, opioids for diarrhea, and tricyclic antidepressants for IBS pain.

They are all manipulating the brain's primary neurotransmitters.

The gastrointestinal tract essentially operates on the exact same chemical language as the human brain.

Wow.

It is a profound reminder of the intricate, inseparable wiring of the gut -brain axis.

It really changes the way you look at the entire system.

Well, from all of us on the Last Minute Lecture team, thank you for joining this deep dive.

Good luck out there.

Good luck mastering these concepts for your clinical practice, and we'll catch you next time.